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Probiotics have been shown to reduce the risk of necrotising enterocolitis (NEC) in very low birthweight babies without adverse effects in 
RCTs studying >5000 babies1-2. 
  
Since January 2013, our tertiary-level NICU has offered probiotics routinely to high-risk neonates to prevent necrotising enterocolitis, using 
dual-strain Lactobacillus-Bifidobacteria (Infloran or Labinic). 
 
Prior to reviewing the effect of probiotics on NEC and death rates within our clinical setting, it was noted that a 2016 retrospective 
observational study from the Netherlands did not identify an independent association between probiotic administration and reduced 
incidence of NEC or death3. One limiting factor was noted to be the possibility of untreated infants within the cohort.  Before conducting 
our own study, we therefore audited adherence to local probiotic administration guidelines. 
BACKGROUND AND AIMS 
 
 
Our audit provides an essential foundation for onward research investigating the effect of routine probiotic administration on the incidence 




Using Badgernet neonatal electronic records, we retrospectively 
reviewed probiotic administration in probiotic-eligible babies 





Babies <32 weeks’ gestation or 32-36 weeks’ gestation and 
<1500g birthweight 
 
Dose daily from day 0-1 after birth or transfer in, if the baby is 
eligible for milk feeds  
 
Dose until  weeks’ orre ted age (if orn <  weeks’ 
gestation) or until discharge (VLBW babies born 32- 6 weeks’ 
gestation) 
GUIDELINE FOR PROBIOTIC USE 
51 (14% of those receiving 
probiotic) started at >7 days 
postnatal age 
No reason recorded for delay in 
65% 
476 babies = <32 weeks or <1500g 
52 = 32- 6 weeks’ gestation  
and <1500g 
387 (91%) = Eligible for 
probiotics* 
50 (96%) = Eligible for 
probiotics* 
373 (96%) of eligible babies 
received probiotics 
28 (56%) of eligible babies 
received probiotics 
244 (65% of those receiving 
probiotic) started on day 0-1  
(median start day = day 2, range 
0-44, IQR 1-4 days) 
19 (68% of those receiving 
probiotic) started on day 0-1  
(median start day = day 1.5, 
range 0-19, IQR 1-4) 
349 (94% of those receiving 
probiotic) continued until >34 
weeks corrected age or transfer 
25 (89% of those receiving 
probiotic)= continued until 
discharge or transfer 
 = <  weeks’ gestation 
2 (7% of those receiving 
probiotic) started at >7 days 
postnatal age 
No reason recorded for delay in 
50% 
* Exclusion criteria: Seriously unwell (ie not eligible for milk 




Results of the audit are shown in figure 1. 
 
Adherence to our local probiotic guideline was good for babies 
<32 weeks’ gestation, but relatively poor for more mature 
preterm VLBW babies who are also at an increased risk for NEC. 
Reasons for delays or omissions were poorly recorded. Good 
compliance is important to optimise NEC prevention. 
RESULTS AND CONCLUSIONS 
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